Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Biojiva LLC is currently navigating 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 6 actions are being handled by 6 distinct examiners, meaning each case is under the review of a different person. The portfolio is distributed across 6 distinct art units, which indicates that each pending action is also in a separate art unit.
The busiest examiner for Biojiva LLC is HUI, SAN MING R, who has 1 pending office action. This 1 action is part of the 6 total pending office actions for the company. Since there are 6 distinct examiners for 6 pending actions, the workload is evenly spread, and no single examiner has a dominant influence over the portfolio.
The 6 distinct art units involved suggest that the company's Biotechnology & Pharmaceuticals applications cover several different technical niches. Practitioners should be prepared to adapt their arguments to the specific standards of these 6 distinct art units while managing the 6 distinct examiners involved. This distribution of actions to examiners and art units suggests a highly diversified prosecution landscape.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUI, SAN MING R | 1 | 59.6% | +20.0% |
| CARR, DEBORAH D | 1 | 81.8% | +2.9% |
| FAN, LYNN Y | 1 | 47.3% | +49.8% |
| SCHMITT, MICHAEL J | 1 | 57.0% | +20.4% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
| HAQ, SHAFIQUL | 1 | 64.8% | +55.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18275972 | Methods for Inhibiting the Progression of Neurodegenerative Diseases | INAM, SAHAR | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18772745 | SITE-SPECIFIC ISOTOPIC LABELING OF 1,4-DIENE SYSTEMS | CARR, DEBORAH D | — |
| 18767538 | Methods for Treating Tauopathy | FAN, LYNN Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18167781 | METHODS FOR MONITORING PATIENT RESPONSE TO TREATMENT OF RETINAL OXIDATIVE DISEASES | HAQ, SHAFIQUL | 46d |
| 18863394 | Therapeutic Methods for Treating ALS | HUI, SAN MING R | — |
| 18767538 | Methods for Treating Tauopathy | FAN, LYNN Y | — |
| 18541375 | SYNERGISTIC COMBINATION THERAPY FOR TREATING ALS | SCHMITT, MICHAEL J | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1691 | 1 |
| 1759 | 1 |
| 1629 | 1 |
| 1622 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18863394 | Therapeutic Methods for Treating ALS | HUI, SAN MING R | 1627 | §103Other | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18772745 | SITE-SPECIFIC ISOTOPIC LABELING OF 1,4-DIENE SYSTEMS | CARR, DEBORAH D | 1691 | §103§112Other | Non-Final OA | — | Pending | Jul 15, 2024 |
| 18767538 | Methods for Treating Tauopathy | FAN, LYNN Y | 1759 | §103§112 | Non-Final OA | — | Pending | Jul 09, 2024 |
| 18541375 | SYNERGISTIC COMBINATION THERAPY FOR TREATING ALS | SCHMITT, MICHAEL J | 1629 | §103DP | Final Rejection | — | Pending | Dec 15, 2023 |
| 18275972 | Methods for Inhibiting the Progression of Neurodegenerative Diseases | INAM, SAHAR | 1622 | §102§103§112DP | Non-Final OA | — | Pending | Aug 04, 2023 |
| 18167781 | METHODS FOR MONITORING PATIENT RESPONSE TO TREATMENT OF RETINAL OXIDATIVE DISEASES | HAQ, SHAFIQUL | 1678 | §103Other | Final Rejection | 46d | Pending | Feb 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBiojiva LLC has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
San Ming R Hui has the most, with 1 of Biojiva LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
